S&P 500   4,282.72 (+0.22%)
DOW   33,606.10 (-0.04%)
QQQ   355.68 (+0.42%)
AAPL   170.70 (-0.73%)
MSFT   313.71 (+0.50%)
META   299.28 (+0.11%)
GOOGL   130.70 (+1.66%)
AMZN   126.63 (+0.52%)
TSLA   241.71 (-0.99%)
NVDA   426.96 (+1.87%)
NIO   8.48 (+0.83%)
BABA   86.38 (+0.55%)
AMD   98.96 (+3.13%)
T   14.88 (-0.93%)
F   12.41 (-0.16%)
MU   68.50 (+0.82%)
CGC   0.92 (-0.53%)
GE   111.10 (+1.06%)
DIS   80.21 (+0.20%)
AMC   7.62 (-3.67%)
PFE   32.17 (-0.71%)
PYPL   57.48 (-2.46%)
NFLX   380.00 (+0.20%)
S&P 500   4,282.72 (+0.22%)
DOW   33,606.10 (-0.04%)
QQQ   355.68 (+0.42%)
AAPL   170.70 (-0.73%)
MSFT   313.71 (+0.50%)
META   299.28 (+0.11%)
GOOGL   130.70 (+1.66%)
AMZN   126.63 (+0.52%)
TSLA   241.71 (-0.99%)
NVDA   426.96 (+1.87%)
NIO   8.48 (+0.83%)
BABA   86.38 (+0.55%)
AMD   98.96 (+3.13%)
T   14.88 (-0.93%)
F   12.41 (-0.16%)
MU   68.50 (+0.82%)
CGC   0.92 (-0.53%)
GE   111.10 (+1.06%)
DIS   80.21 (+0.20%)
AMC   7.62 (-3.67%)
PFE   32.17 (-0.71%)
PYPL   57.48 (-2.46%)
NFLX   380.00 (+0.20%)
S&P 500   4,282.72 (+0.22%)
DOW   33,606.10 (-0.04%)
QQQ   355.68 (+0.42%)
AAPL   170.70 (-0.73%)
MSFT   313.71 (+0.50%)
META   299.28 (+0.11%)
GOOGL   130.70 (+1.66%)
AMZN   126.63 (+0.52%)
TSLA   241.71 (-0.99%)
NVDA   426.96 (+1.87%)
NIO   8.48 (+0.83%)
BABA   86.38 (+0.55%)
AMD   98.96 (+3.13%)
T   14.88 (-0.93%)
F   12.41 (-0.16%)
MU   68.50 (+0.82%)
CGC   0.92 (-0.53%)
GE   111.10 (+1.06%)
DIS   80.21 (+0.20%)
AMC   7.62 (-3.67%)
PFE   32.17 (-0.71%)
PYPL   57.48 (-2.46%)
NFLX   380.00 (+0.20%)
S&P 500   4,282.72 (+0.22%)
DOW   33,606.10 (-0.04%)
QQQ   355.68 (+0.42%)
AAPL   170.70 (-0.73%)
MSFT   313.71 (+0.50%)
META   299.28 (+0.11%)
GOOGL   130.70 (+1.66%)
AMZN   126.63 (+0.52%)
TSLA   241.71 (-0.99%)
NVDA   426.96 (+1.87%)
NIO   8.48 (+0.83%)
BABA   86.38 (+0.55%)
AMD   98.96 (+3.13%)
T   14.88 (-0.93%)
F   12.41 (-0.16%)
MU   68.50 (+0.82%)
CGC   0.92 (-0.53%)
GE   111.10 (+1.06%)
DIS   80.21 (+0.20%)
AMC   7.62 (-3.67%)
PFE   32.17 (-0.71%)
PYPL   57.48 (-2.46%)
NFLX   380.00 (+0.20%)
NASDAQ:EVOK

Evoke Pharma (EVOK) Stock Forecast, Price & News

$1.08
0.00 (0.00%)
(As of 01:29 PM ET)
Compare
Today's Range
$0.99
▼
$1.10
50-Day Range
$0.96
▼
$1.73
52-Week Range
$0.92
▼
$5.96
Volume
1,196 shs
Average Volume
26,041 shs
Market Capitalization
$3.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

EVOK stock logo

About Evoke Pharma (NASDAQ:EVOK) Stock

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

EVOK Price History

EVOK Stock News Headlines

September 23, 2023 | americanbankingnews.com
Evoke Pharma (NASDAQ:EVOK) Shares Cross Below Two Hundred Day Moving Average of $1.77
September 23, 2023 | americanbankingnews.com
Evoke Pharma (NASDAQ:EVOK) Receives New Coverage from Analysts at StockNews.com
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 14, 2023 | finanznachrichten.de
Evoke Pharma, Inc.: Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI
September 14, 2023 | finance.yahoo.com
Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®
August 15, 2023 | finance.yahoo.com
Evoke launches audience intelligence offering to unlock full commercial potential of life sciences brands
August 10, 2023 | msn.com
Evoke Pharma GAAP EPS of -$0.56 beats by $0.17, revenue of $1.13M beats by $0.03M
August 10, 2023 | finanznachrichten.de
Evoke Pharma, Inc.: Evoke Pharma Reports Second Quarter 2023 Financial Results
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 10, 2023 | finance.yahoo.com
Evoke Pharma Reports Second Quarter 2023 Financial Results
August 8, 2023 | msn.com
Mayo's Aidan O'Shea and fiancée Kristin celebrate engagement in exotic location
August 7, 2023 | finance.yahoo.com
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
August 3, 2023 | forbes.com
The Psychology Of Color: 5 Ways You Can Use Color To Build Brand Identity
July 29, 2023 | msn.com
Feeling like a winner: Mayo's Aidan O'Shea pops the question
July 25, 2023 | finance.yahoo.com
Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting
July 15, 2023 | msn.com
10 surprising facts you never knew about Sudocrem
July 5, 2023 | finance.yahoo.com
EV00.BE - Evoke Pharma Inc
June 14, 2023 | finance.yahoo.com
Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment
May 17, 2023 | marketwatch.com
2023, Gastroenterology Market Growth Status and Outlook- 2030
May 16, 2023 | finanznachrichten.de
Evoke Pharma, Inc.: Evoke Pharma Reports First Quarter 2023 Financial Results
May 15, 2023 | benzinga.com
Evoke Pharma Reports First Quarter 2023 Financial Results
May 15, 2023 | msn.com
Evoke Pharma GAAP EPS of -$0.67 misses by $0.09, revenue of $0.81M misses by $0.19M
May 9, 2023 | finance.yahoo.com
Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources
May 4, 2023 | finance.yahoo.com
Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023
April 20, 2023 | finance.yahoo.com
United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI
April 9, 2023 | marketwatch.com
8-K: Evoke Pharma Inc
April 6, 2023 | finanznachrichten.de
Evoke Pharma, Inc.: Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent
See More Headlines
Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

EVOK Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVOK
CUSIP
N/A
CIK
1403708
Web
www.evokepharma.com
Phone
(858) 345-1494
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,220,000.00
Net Margins
-222.13%
Pretax Margin
-222.13%
Return on Equity
-258.20%
Return on Assets
-71.61%

Debt

Debt-to-Equity Ratio
9.29
Current Ratio
4.29
Quick Ratio
4.04

Sales & Book Value

Annual Sales
$2.51 million
Price / Sales
1.38
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.22 per share
Price / Book
0.85

Miscellaneous

Outstanding Shares
3,340,000
Free Float
2,949,000
Market Cap
$3.46 million
Optionable
Not Optionable
Beta
0.37
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. David A. Gonyer R.Ph. (Age 59)
    Co-Founder, CEO & Director
    Comp: $806.53k
  • Mr. Matthew J. D'Onofrio MBA (Age 53)
    Co-Founder, Pres & COO
    Comp: $557.11k
  • Dr. Marilyn R. Carlson (Age 75)
    Chief Medical Officer
    Comp: $518.14k
  • Mr. Christopher Quesenberry
    Chief Commercial Officer - Gimoti (TM)

Key Competitors

View All Competitors













EVOK Stock - Frequently Asked Questions

How have EVOK shares performed in 2023?

Evoke Pharma's stock was trading at $2.68 at the start of the year. Since then, EVOK shares have decreased by 61.4% and is now trading at $1.0350.
View the best growth stocks for 2023 here.

Are investors shorting Evoke Pharma?

Evoke Pharma saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 17,700 shares, an increase of 391.7% from the August 31st total of 3,600 shares. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is currently 1.4 days. Approximately 0.5% of the shares of the company are sold short.
View Evoke Pharma's Short Interest.

When is Evoke Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our EVOK earnings forecast.

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) issued its quarterly earnings data on Thursday, August, 10th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $1.13 million for the quarter. Evoke Pharma had a negative net margin of 222.13% and a negative trailing twelve-month return on equity of 258.20%.

When did Evoke Pharma's stock split?

Shares of Evoke Pharma reverse split on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $1.04.

How much money does Evoke Pharma make?

Evoke Pharma (NASDAQ:EVOK) has a market capitalization of $3.46 million and generates $2.51 million in revenue each year. The specialty pharmaceutical company earns $-8,220,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The official website for the company is www.evokepharma.com. The specialty pharmaceutical company can be reached via phone at (858) 345-1494 or via email at tbui@theruthgroup.com.

This page (NASDAQ:EVOK) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -